Merck, GE team for AD treatment research

Editorial Staff | | Health Imaging | Molecular Imaging

Merck and GE Healthcare have made a clinical study collaboration, license and supply agreement for the PET imaging agent [18F]Flutemetamol to support Merck’s development of MK-8931, the company’s lead investigational candidate for Alzheimer’s disease (AD).

MK-8931 is an oral beta amyloid precursor protein site cleaving enzyme inhibitor designed to modify disease progression and improve symptom control, according to a press release from Merck and GE.

Under the agreement, GE will supply [18F]Flutemetamol for patient selection during clinical trials and to evaluate the MK-8931 agent. A joint Merck and GE Imaging Advisory Committee will oversee the planned imaging studies.

Editorial Staff

Related Content

PET method offers new insight into inflammation of the brain
New PET imaging method could improve our understanding of long COVID
FDA approves new prostate cancer imaging agent with extended shelf life
New PET study offers insight into how dopamine drives executive function
New radiopharmaceutical targeted at gastrointenstinal cancers yields impressive results
New PET method combines antibody with radioactive isotope to improve lung cancer detection

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.